Clinical Research Directory
Browse clinical research sites, groups, and studies.
Dexrazoxane to Protect Against Hemorrhagic STEMI
Sponsor: Rohan Dharmakumar
Summary
This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).
Official title: Dexrazoxane for the Reduction of Haemorrhagic Myocardial Infarction in STEMI: A Double-Blind, Placebo-Controlled, Sequential-Cohort Phase IIa Trial
Key Details
Gender
All
Age Range
18 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-08-30
Completion Date
2026-03-16
Last Updated
2026-05-26
Healthy Volunteers
No
Conditions
Interventions
Dexrazoxane
Intravenous infusion administered adjunctively to primary PCI
Normal Saline
Visually identical placebo infusion (Normal Saline 0.9% NaCl) of similar volume administered adjunctively to primary percutaneous coronary intervention (PCI). Administered at four timepoints: emergency room (pre-PCI), 4 hours, 8 hours, and 12 hours post-primary PCI, identical in appearance, volume, and schedule to the investigational product.
Locations (1)
Synergy Cardiovascular Research Center
Rajkot, India